WCLC 2025 - Posters & ePosters-P2.08 .34 Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Single-Arm Study

P2.08 .34 Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Single-Arm Study

Back to course

Pdf Summary

This prospective single-arm study evaluated the efficacy and safety of serplulimab combined with chemotherapy as neoadjuvant treatment in patients with locally advanced non-small cell lung cancer (NSCLC) stages II to IIIB. A total of 55 patients (median age 66) with mostly squamous cell carcinoma (81.8%) and ECOG performance status 1 were enrolled. Adenocarcinoma comprised 16.4% and undifferentiated carcinoma 1.8%. Key inclusion criteria ensured resectable or potentially resectable disease without driver mutations in adenocarcinoma cases.<br /><br />The therapeutic regimen included serplulimab 300 mg IV every 3 weeks alongside chemotherapy: pemetrexed plus carboplatin for adenocarcinoma, and albumin-bound paclitaxel plus carboplatin for non-adenocarcinoma histologies. After neoadjuvant therapy, 42 patients completed imaging evaluation, and 40 underwent curative-intent surgery with a 100% R0 resection rate. Major pathologic response (MPR) was achieved in 67.5% of patients (27/40), and pathologic complete response (pCR) in 37.5% (15/40). Radiographic responses included 2 complete responses (4.8%), 38 partial responses (90.5%), and 2 stable disease cases (4.8%), yielding an objective response rate (ORR) of 95.2%. <br /><br />Adverse events occurred in 36.4% (20/55) of patients, with 9.1% experiencing grade 3 toxicities. Six patients discontinued treatment due to adverse events, but no surgical delays were reported from treatment toxicity. One serious perioperative complication—bronchopleural fistula—occurred but was successfully managed.<br /><br />The interim results indicate that serplulimab plus chemotherapy is a promising, tolerable neoadjuvant approach for locally advanced NSCLC, supporting further investigation with continued enrollment and longer follow-up to confirm these observations.

Asset Subtitle

Jian Zeng

Meta Tag

Speaker Jian Zeng

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

serplulimab

neoadjuvant therapy

non-small cell lung cancer

NSCLC

chemotherapy

squamous cell carcinoma

adenocarcinoma

pathologic complete response

major pathologic response

adverse events